STOCK TITAN

Ocuphire Pharma Inc - OCUP STOCK NEWS

Welcome to our dedicated news page for Ocuphire Pharma (Ticker: OCUP), a resource for investors and traders seeking the latest updates and insights on Ocuphire Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ocuphire Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ocuphire Pharma's position in the market.

Rhea-AI Summary
Ocuphire Pharma to participate in upcoming investment conferences and panel presentations
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
conferences
-
Rhea-AI Summary
Ocuphire Pharma to present clinical data on APX3330 and Nyxol® at ESCRS congress and MODLive! Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.45%
Tags
conferences
-
Rhea-AI Summary
Ocuphire Pharma's ZETA-1 abstract receives award distinction at WIO. APX3330 shows statistical significance in preventing progression of diabetic retinopathy. Potential to shift treatment paradigm in DR.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
none
Rhea-AI Summary
Ocuphire Pharma, Inc. announced financial results for Q2 2023, with a cash balance of $40 million expected to fund operations into 2025. They have scheduled an End-of-Phase 2 meeting with the FDA for Q4 2023 for their oral APX3330 in Diabetic Retinopathy. They also have a Common Share Purchase Agreement with Lincoln Park Capital Fund, LLC providing up to $50 million in financing over 30 months. Nyxol RM has a PDUFA date of September 28, 2023, with potential approval triggering a $10 million milestone payment to Ocuphire.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
-
Rhea-AI Summary
Ocuphire Pharma, a clinical-stage ophthalmic biopharmaceutical company (Nasdaq: OCUP), announced their participation in the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference. Ronil Patel, MS, SVP of Operations and Business Development, and Charlie Hoffmann, MBA, SVP of Corporate Development, will present a company overview and participate in panel discussions. The company aims to develop and commercialize small-molecule therapies for retinal and refractive eye disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.43%
Tags
conferences
-
Rhea-AI Summary
Ocuphire Pharma, Inc. will present ZETA-1 Phase 2 trial data evaluating APX3330 in diabetic retinopathy at the ASRS annual scientific meeting. The company has scheduled an End-of-Phase 2 meeting with the FDA for Q4 2023 to discuss the APX3330 development program. The drug achieved statistical significance in preventing clinically meaningful progression of diabetic retinopathy, positioning it as a potential non-invasive, oral, early treatment for NPDR patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
conferences
Rhea-AI Summary
Ocuphire Pharma approves equity award for new hire
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.37%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.65%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.78%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.2%
Tags
none
Ocuphire Pharma Inc

Nasdaq:OCUP

OCUP Rankings

OCUP Stock Data

45.66M
23.80M
6.98%
15.15%
6.33%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Rockville

About OCUP

ocuphire is a new biopharmaceuticals company focused on developing and commercializing small molecule drugs for unmet medical needs in the ocular disease space. ocuphire’s lead drug candidate, nyxol eye drops, is aimed to treat patients with night vision disturbances (nvd), glaucoma and presbyopia (impaired near-term vision). ocuphire is in discussions with a prospective late stage ophthalmic drug program that could be developed in parallel. ocuphire's management team has over 100 years of drug development expertise across a diverse set of therapeutic areas including ophthalmology, orphan, cardio-metabolic, nephrology, oncology and respiratory.